EU calls for a return to full dosing of Genzyme's Fabrazyme

10/24/2010 | Reuters

The European Medicines Agency has recommended that doctors resume prescribing the full dose of Genzyme's Fabry disease drug Fabrazyme after the agency found a steady increase in adverse events among patients receiving a lower dose. Dosing of the treatment was reduced last year because of a supply shortage prompted by issues at Genzyme's manufacturing facility.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
Catheter Engineer
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
MANAGER MEDICAL GAS COMPLIANCE AND SAFETY
Matheson Tri-Gas, Inc.
Houston, TX
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations